Date of birth: October 1, 1957
Appointment as a director of Meiji Holdings: June 2025
Number of Meiji Holdings' shares held: 19,022 (as of May 31, 2025)

Toshiaki Nagasato is in charge of the Meiji Group's entire pharmaceutical business as a chief operating officer. He also serves as president of Meiji Seika Pharma Co., Ltd., and as chairman of KM Biologics Co., Ltd.

Toshiaki has been active in the Meiji Group's evolution and growth for over four decades since he joined Meiji Seika Kaisha Ltd. in 1983. In China, in particular, following his appointment as general manager of Meiji Lukang Pharmaceutical Co., Ltd., established in 2003, he helped lay the foundations of its operations and drive its business expansion.

In 2014, Meiji Seika Pharma appointed Toshiaki as general manager of its production division and executive officer in charge of its bioscience laboratory. In those roles, he helped improve production processes and contributed to advancements in R&D.

Toshiaki also led the reorganization of KM Biologics following his appointment as president in 2018, primarily by installing production systems and improving auditing processes to strengthen corporate governance and compliance systems. He also renewed its management principles and code of conduct, making a significant contribution to raising the company's credibility.

In April 2022, Toshiaki was appointed as a director at Meiji Animal Health Co., Ltd., where he has been overseeing a wide range of initiatives in the veterinary medicine market.

In consideration of Toshiaki's abundant experience and expertise, Meiji Holdings appointed him as chief operating officer of the Pharmaceutical Segment in June 2025.